Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: The Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION) is a pragmatic randomised controlled trial of the effectiveness of intensified multi-factorial treatment on 5 year cardiovascular morbidity and mortality rates in people with screen-detected type 2 diabetes in the Netherlands, UK and Denmark. This paper describes the baseline characteristics of the study population, their estimated risk of coronary heart disease and the extent to which that risk is potentially modifiable. METHODS: Stepwise screening strategies were performed using risk questionnaires and routine general practice data plus random blood glucose, HbA(1c) and fasting blood glucose measurement. Diabetes was diagnosed using the 1999 World Health Organization criteria and estimated 10 year coronary heart disease risk was calculated using the UK Prospective Diabetes Study risk engine. RESULTS: Between April 2001 and December 2006, 3,057 people with screen-detected diabetes were recruited to the study (mean age 59.7 years, 58% men) after a stepwise screening programme involving 76,308 people screened in 334 general practices in three countries. Their median estimated 10 year risk of coronary heart disease was 11% in women (interquartile range 7-16%) and 21% (15-30%) in men. There were differences in the distribution of risk factors by country, linked to differences in approaches to screening and the extent to which risk factors had already been detected and treated. The mean HbA(1c) at recruitment was 7.0% (SD 1.6%). Of the people recruited, 73% had a blood pressure > or =140/90 and of these 58% were not on antihypertensive medication. Cholesterol levels were above 5.0 mmol/l in 70% of participants, 91% of whom were not being treated with lipid-lowering drugs. CONCLUSIONS/INTERPRETATION: People with type 2 diabetes detected by screening and included in the ADDITION study have a raised and potentially modifiable risk of CHD. ClinicalTrials.gov ID no.: NCT 00237549.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Guillemin, F., Bombardier, C., & Beaton, D. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90142-n · Cited by 6,060
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 1×
“hyperglycaemia (5-8) hypertension (12-14) and dyslipidaemia (15;16), screening and earlier initiation of such treatment has been the subject of considerable debate (17-19).”
BackgroundPyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · cited 1×
“Given the high prevalence of undiagnosed diabetes [9–11] and the evidence that in people with clinically diagnosed diabetes the risk of complications can be effectively reduced by intensive treatment of hyperglycaemia [5–8 ]h ypertension [12–14] and dyslipidaemia [ 15 , 16], screening and earlier initiation of such tr…”
BackgroundLindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis
Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.815 · Cited by 1,306
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084 · cited 1×
“UKPDS risk engine The estimated absolute ten year risk of coronary heart disease (CHD) was calculated using the previously published UKPDS risk engine (27).”
MethodCollins, R., Armitage, J., Parish, S., Sleight, P., & Peto, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12475-0 · Cited by 492
Prevalences of Diabetes and Impaired Glucose Regulation in a Danish Population
Glümer, C., Jørgensen, T., & Borch-Johnsen, K. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2335 · Cited by 279
Self-citationWhat determines the cost-effectiveness of diabetes screening?
Glümer, C., Yuyun, M., Griffin, S., Farewell, D., Spiegelhalter, D., Kinmonth, A. L., & Wareham, N. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0248-x · Cited by 54 · cited 1×
“A key uncertainty factor in assessing the balance between the costs and benefits of implementing policies for early detection of diabetes is the magnitude of cardiovascular risk reduction following early detection and intensive therapy [ 11 ].”
BackgroundSelf-citation
Cited by
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462
Self-citationHerman, W. H., Ye, W., Griffin, S. J., Simmons, R. K., Davies, M. J., Khunti, K., Rutten, G. E. H. M., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2459 · Cited by 340
Self-citationJenum, A. K., Mørkrid, K., Sletner, L., Vange, S., Torper, J. L., Nakstad, B., Voldner, N., Rognerud-Jensen, O. H., Berntsen, S., Mosdøl, A., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0866 · Cited by 290
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62162-0 · Cited by 287
Self-citationA 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus
on behalf of the Utrecht Diabetic Encephalopathy Study Group, van den Berg, E., Reijmer, Y. D., de Bresser, J., Kessels, R. P. C., Kappelle, L. J., & Biessels, G. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1571-9 · Cited by 254
Metadata
- Authors
- Sandbaek, A., Griffin, S. J., Rutten, G., Davies, M., Stolk, R., Khunti, K., Borch-Johnsen, K., Wareham, N. J., & Lauritzen, T.
- Venue
- Diabetologia
- Published
- 2008-04-29
- Volume
- 51
- Issue
- 7
- Pages
- 1127-1134
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2116372723
- Cited by
- 97
- References
- 13
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.